Mohamed H S Awwad1, Katharina Kriegsmann1, Julian Plaumann1, Michael Benn1, Jens Hillengass1, Marc S Raab1, Uta Bertsch1,2, Markus Munder3, Katja Weisel4, Hans Jürgen Salwender5, Mathias Hänel6, Roland Fenk7, Jan Dürig8, Carsten Müller-Tidow1, Hartmut Goldschmidt1,2, Michael Hundemer1. 1. Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany. 2. National Center for Tumour Diseases, University of Heidelberg, Heidelberg, Germany. 3. Department of Hematology, Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. 4. Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany. 5. Asklepios Klinik Hamburg Altona, Germany. 6. Klinikum Chemnitz, Germany. 7. Department of Hematology, Oncology and Clinical Immunology, University Düsseldorf, Düsseldorf, Germany. 8. Department of Hematology, University of Essen, Essen, Germany.
Abstract
Purpose: While recent studies described the role of IKZF1/3 proteins in multiple myeloma (MM) cells, few have highlighted the significance of IKZF1/3 expression in T-cells. In this study we examine the prognostic and predictive value of IKZF1/3 expression in T-cells in patients with MM stage III. Experimental design: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value. We also combined in vivo observations with in vitro assays to determine the effect of IKZF1/3 expression on the T-cell immunophenotype and anti-tumour T-cell response in 162 MMIII patients. Results: We found that high IKZF3, but not IKZF1, expression in T-cells correlates with superior overall survival in MMIII patients treated with immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide). Moreover, we show that higher IKZF3 expression in T-cells inhibits myeloma-specific T-cell response in vitro and that the immunophenotype of patients with high IKZF3 expression shows features that are contrary to the changes induced by immunomodulatory drugs. Although we observed higher IKZF3 expression levels in T-cells from patients with MMIII compared to MMI, IKZF3 expression was unaffected by the tumour microenvironment. Conclusion: In conclusion, IKZF3 expression in T-cells is a predictive value for clinical outcome in MMIII patients treated with immunomodulatory drugs due to its profound modulation of T-cell functionality.
Purpose: While recent studies described the role of IKZF1/3 proteins in multiple myeloma (MM) cells, few have highlighted the significance of IKZF1/3 expression in T-cells. In this study we examine the prognostic and predictive value of IKZF1/3 expression in T-cells in patients with MM stage III. Experimental design: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value. We also combined in vivo observations with in vitro assays to determine the effect of IKZF1/3 expression on the T-cell immunophenotype and anti-tumour T-cell response in 162 MMIII patients. Results: We found that high IKZF3, but not IKZF1, expression in T-cells correlates with superior overall survival in MMIII patients treated with immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide). Moreover, we show that higher IKZF3 expression in T-cells inhibits myeloma-specific T-cell response in vitro and that the immunophenotype of patients with high IKZF3 expression shows features that are contrary to the changes induced by immunomodulatory drugs. Although we observed higher IKZF3 expression levels in T-cells from patients with MMIII compared to MMI, IKZF3 expression was unaffected by the tumour microenvironment. Conclusion: In conclusion, IKZF3 expression in T-cells is a predictive value for clinical outcome in MMIII patients treated with immunomodulatory drugs due to its profound modulation of T-cell functionality.
Authors: J Krönke; F Kuchenbauer; M Kull; V Teleanu; L Bullinger; D Bunjes; A Greiner; S Kolmus; S Köpff; M Schreder; L-O Mügge; C Straka; M Engelhardt; H Döhner; H Einsele; F Bassermann; R Bargou; S Knop; C Langer Journal: Leukemia Date: 2016-12-26 Impact factor: 11.528
Authors: Kartik Sehgal; Rituparna Das; Lin Zhang; Rakesh Verma; Yanhong Deng; Mehmet Kocoglu; Juan Vasquez; Srinivas Koduru; Yan Ren; Maria Wang; Suzana Couto; Mike Breider; Donna Hansel; Stuart Seropian; Dennis Cooper; Anjan Thakurta; Xiaopan Yao; Kavita M Dhodapkar; Madhav V Dhodapkar Journal: Blood Date: 2015-04-13 Impact factor: 22.113
Authors: Maximilian Merz; Thomas Hielscher; Anja Seckinger; Dirk Hose; Elias K Mai; Marc S Raab; Hartmut Goldschmidt; Anna Jauch; Jens Hillengass Journal: Am J Hematol Date: 2016-09-03 Impact factor: 10.047
Authors: C Song; X Pan; Z Ge; C Gowda; Y Ding; H Li; Z Li; G Yochum; M Muschen; Q Li; K J Payne; S Dovat Journal: Leukemia Date: 2015-12-07 Impact factor: 11.528
Authors: Michael L Ridley; Veerle Fleskens; Ceri A Roberts; Sylvine Lalnunhlimi; Aldana Alnesf; Aoife M O'Byrne; Kathryn J A Steel; Giovanni A M Povoleri; Jonathan Sumner; Paul Lavender; Leonie S Taams Journal: J Immunol Date: 2020-04-22 Impact factor: 5.422
Authors: Anu Laulajainen-Hongisto; Annina Lyly; Paula Kauppi; Sanna Toppila-Salmi; Tanzeela Hanif; Kishor Dhaygude; Matti Kankainen; Risto Renkonen; Kati Donner; Pirkko Mattila; Tuomas Jartti; Jean Bousquet Journal: Clin Transl Allergy Date: 2020-10-28 Impact factor: 5.871
Authors: Mohamed H S Awwad; Abdelrahman Mahmoud; Heiko Bruns; Hakim Echchannaoui; Katharina Kriegsmann; Raphael Lutz; Marc S Raab; Uta Bertsch; Markus Munder; Anna Jauch; Katja Weisel; Bettina Maier; Niels Weinhold; Hans Jürgen Salwender; Volker Eckstein; Mathias Hänel; Roland Fenk; Jan Dürig; Benedikt Brors; Axel Benner; Carsten Müller-Tidow; Hartmut Goldschmidt; Michael Hundemer Journal: Leukemia Date: 2021-02-17 Impact factor: 11.528